June 26, 2020 — Accuray Incorporated announced the company has launched the CyberKnife S7 System, an innovative device combining speed, advanced precision and real-time artificial intelligence (AI)-driven motion tracking and synchronization treatment delivery for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments — in as little as 15 minutes. The CyberKnife S7 System is the next-generation CyberKnife platform, a robotic, non-invasive radiation therapy device capable of treating cancerous and benign tumors throughout the body, as well as neurologic disorders. The new CyberKnife technology is the most recent illustration of Accuray innovation in radiation therapy that empowers healthcare providers through new capabilities to provide the best possible care to their patients.
Many changes can happen during treatment: the patient shifts position, breathes, or coughs, muscles tense and relax, fluids and gasses displace internal organs. This movement can impact the location of the tumor target when the radiation beam is delivered. The CyberKnife System’s Synchrony motion synchronization technology uses AI to adapt radiation delivery in real-time to patient and/or tumor movement throughout the course of treatment. The system’s robotic design facilitates the delivery of radiation from potentially thousands of unique angles, significantly expanding the possible positions from which radiation beams can be delivered. The more angles and points in space from which to approach the tumor, the better a physician will be able to maximize radiation dose delivered to the tumor and minimize dose to surrounding healthy tissues. The CyberKnife System is the only device capable of delivering sub-millimetric stereotactic treatments anywhere in the body with speed, efficiency and accuracy — all without the need for human intervention.
“Geisinger is dedicated to making exceptional cancer care available to residents of northeastern Pennsylvania, within their community,” said chairman of radiation oncology at Geisinger Cancer Institute, Anand Mahadevan, M.D. “We are proud to be the first center in the world to treat patients with the CyberKnife S7 System, an advanced device that will expand the scope of tumors we can treat. Knowing that the system will automatically adapt treatment delivery for patient or tumor movement gives us the confidence to use SRS and SBRT for intra- and extra-cranial disease sites throughout the body, providing meaningful benefits to our patients during and after treatment.”
Learn more about the CyberKnife S7 System here.
The CyberKnife S7 is built for the speed clinicians need for operational efficiency. Accurate, sub-millimetric, motion synchronized, (ultra) hypofractionated treatments can be delivered in as little as 15 minutes with Synchrony and the VOLO™ Optimizer, providing the patient throughput necessary to be successful in today’s clinical environment. SRS and SBRT use advanced techniques to deliver precise, hypofractionated radiation therapy — which allows patients to be treated with very high doses of accurately targeted radiation administered in a few days versus conventional fractionation where treatments often require up to 35 visits. Patient benefits can include a shorter overall course of treatment and a significant reduction in the risk of side effects that can significantly impact patients’ lives.
Changes to the proposed Medicare & Medicaid Radiation Oncology – Alternative Payment Model favor the delivery of hypofractionated radiotherapy whenever clinically appropriate. Radiotherapy devices like the CyberKnife platform provide a resource for hospitals to achieve both their clinical efficacy and ROI goals.
“We are gratified to have achieved this important CyberKnife System milestone with the support from Dr. Mahadevan and his team. The CyberKnife system has continued to evolve since the first patient was treated more than 25 years ago and it remains the ‘go to’ device for clinicians who want to confidently deliver precise and accurate stereotactic treatments on a day-in, day-out basis,” said Joshua H. Levine, president and CEO at Accuray. “With the introduction of the CyberKnife S7 System, Accuray is continuing its legacy of
innovation. We believe this new system will make it easier for Geisinger clinicians to successfully deliver SRS and SBRT and achieve their patient-first treatment objectives, a priority for their team and ours.”
For more information: www.accuray.com